Ramosetron

Generic Name
Ramosetron
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C17H17N3O
CAS Number
132036-88-5
Unique Ingredient Identifier
7ZRO0SC54Y
Background

Ramosetron is a serotonin 5-HT3 receptor antagonist commonly employed to treat nausea and vomiting, in addition to certain diarrheal conditions. It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron. Currently, ramosetron is only approved for use Japan and in certain Southeast Asian...

Indication

For the treatment of nausea and vomiting and diarrhea-predominant irritable bowel syndrome in males.

Associated Conditions
Gastrointestinal Symptoms caused by cancer treatment
Associated Therapies
-

Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-03-07
Last Posted Date
2016-03-22
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
96
Registration Number
NCT01806948
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam Si, Gyeonggi Do, Korea, Republic of

Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation

Phase 2
Conditions
Interventions
First Posted Date
2013-02-11
Last Posted Date
2014-12-08
Lead Sponsor
The Catholic University of Korea
Target Recruit Count
65
Registration Number
NCT01788605
Locations
🇰🇷

Catholic Blood & Marrow Transplantation Center, Seoul St Mary's Hospital, the Catholic University of Korea, Seoul, Korea, Republic of

Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension

First Posted Date
2012-08-20
Last Posted Date
2012-08-20
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
100
Registration Number
NCT01669213
Locations
🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2012-07-11
Last Posted Date
2015-05-08
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
49
Registration Number
NCT01637545
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone

First Posted Date
2012-02-22
Last Posted Date
2012-10-03
Lead Sponsor
Hallym University Medical Center
Target Recruit Count
338
Registration Number
NCT01536691
Locations
🇰🇷

Hyo Jung Kim, Anyang, Gyeonggi-do, Korea, Republic of

Palonosetron Versus Ramosetron for the Prevention of Postoperative Nausea and Vomiting

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2011-11-22
Last Posted Date
2011-11-22
Lead Sponsor
Incheon St.Mary's Hospital
Target Recruit Count
100
Registration Number
NCT01476280
Locations
🇰🇷

Incheon St. Mary's hospital, Incheon, Korea, Republic of

Effect of Ramosetron on Bowel Motility After Colorectal Resection

First Posted Date
2011-09-01
Last Posted Date
2011-09-01
Lead Sponsor
Kyunghee University Medical Center
Target Recruit Count
64
Registration Number
NCT01427127
Locations
🇰🇷

School of Medicine, Kyung Hee University, Seoul, Korea, Republic of

A Study to Evaluate Efficacy of Ramosetron on Diarrhea-predominant Irritable Bowel Syndrome (IBS) in Male Patients

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-10-20
Last Posted Date
2014-10-15
Lead Sponsor
Astellas Pharma Inc
Target Recruit Count
296
Registration Number
NCT01225237

Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery

First Posted Date
2010-07-26
Last Posted Date
2011-11-18
Lead Sponsor
Yonsei University
Target Recruit Count
105
Registration Number
NCT01169805
Locations
🇰🇷

Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of

Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-04-13
Last Posted Date
2012-06-08
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
153
Registration Number
NCT01102491
Locations
🇰🇷

Joint Reconstruction Center, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath